Affimed’s Phase I AFM13 had its Likelihood of Approval (LoA) in B-cell non-Hodgkin lymphoma slashed in half on the back of preclinical data released on 13 May. The data showed that Hodgkin lymphoma patient-derived natural killer (NK) cells, when combined with AFM13, did not reach the same level of cytotoxicity compared with healthy donor-derived NK cells.
AFM13 previously had an LoA of 28%, dropping to 14% as of 17 May. The 14-point drop was determined analysed from a combination of machine learning and proprietary algorithm.
The investigator-led Phase I AFM13 trial is recruiting 30 recurrent or refractory CD30-positive Hodgkin or non-Hodgkin lymphoma patients. AFM13 works by inducing the innate immune system to eliminate CD30-positive hematologic tumour cells. It is the company’s most advanced asset featuring its innate cell engager mechanism.
Affimed has a $1.11bn market cap.
Reynald Castaneda is an Associate Editor for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.